blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2750681

EP2750681 - BRANCHED DISCRETE PEG CONSTRUCTS [Right-click to bookmark this link]
Former [2014/28]BRANCHED DISCRETTE PEG CONSTRUCTS
[2019/45]
StatusNo opposition filed within time limit
Status updated on  03.04.2021
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  24.04.2020
FormerGrant of patent is intended
Status updated on  20.04.2020
FormerExamination is in progress
Status updated on  11.03.2020
FormerGrant of patent is intended
Status updated on  18.11.2019
FormerExamination is in progress
Status updated on  11.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Quanta Biodesign, Ltd.
195 W. Olentangy Street, Suite O
Powell, OH 43065 / US
For all designated states
University of Washington
1107 NE 45th Street
Seattle, WA 98105-4631 / US
[2019/51]
Former [2014/28]For all designated states
Quanta Biodesign, Ltd.
195 W. Olentangy Street, Suite O
Powell, OH 43065 / US
For all designated states
THE UNIVERSITY OF WASHINGTON
1107 N.E. 45th Street
Seattle, WA 98105-4631 / US
Inventor(s)01 / DAVIS, Paul, D.
5824 Springburn Drive
Dublin, OH 43017 / US
02 / WILBUR, D., Scott
6015 137th Place S.W.
Edmonds, WA 98026 / US
 [2014/28]
Representative(s)Lecomte & Partners
76-78, rue de Merl
2146 Luxembourg / LU
[2020/22]
Former [2014/28]Lecomte & Partners
P.O. Box 1623
1016 Luxembourg / LU
Application number, filing date12828094.830.08.2012
[2020/22]
WO2012US53250
Priority number, dateUS201161528915P30.08.2011         Original published format: US 201161528915 P
[2014/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013033476
Date:07.03.2013
Language:EN
[2013/10]
Type: A1 Application with search report 
No.:EP2750681
Date:09.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 07.03.2013 takes the place of the publication of the European patent application.
[2014/28]
Type: B1 Patent specification 
No.:EP2750681
Date:27.05.2020
Language:EN
[2020/22]
Search report(s)International search report - published on:US07.03.2013
(Supplementary) European search report - dispatched on:EP19.02.2015
ClassificationIPC:A61K31/785
[2014/28]
CPC:
C07D209/60 (EP,US); A61K47/60 (EP,US); A61K51/106 (EP,US);
C07C235/08 (EP,US); C07C235/48 (EP,US); C07C271/16 (EP,US);
C07C279/24 (EP,US); C07C317/44 (EP,US); C07C331/28 (EP,US);
C07D207/404 (EP,US); C07D209/48 (EP,US); C07D257/02 (EP,US);
C07D403/14 (EP,US); C07K14/605 (EP,US); C07K16/3069 (EP,US);
C07K16/40 (EP,US); C07C2603/18 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/28]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERZWEIGTE EINZELNE PEG-KONSTRUKTE[2014/28]
English:BRANCHED DISCRETE PEG CONSTRUCTS[2019/45]
French:CONSTRUCTIONS DE PEG DISCRET RAMIFIÉ[2014/28]
Former [2014/28]BRANCHED DISCRETTE PEG CONSTRUCTS
Entry into regional phase19.03.2014National basic fee paid 
19.03.2014Search fee paid 
19.03.2014Designation fee(s) paid 
19.03.2014Examination fee paid 
Examination procedure19.03.2014Examination requested  [2014/28]
18.09.2015Amendment by applicant (claims and/or description)
27.01.2016Despatch of a communication from the examining division (Time limit: M06)
25.07.2016Reply to a communication from the examining division
02.11.2016Despatch of a communication from the examining division (Time limit: M06)
12.05.2017Reply to a communication from the examining division
13.09.2017Despatch of a communication from the examining division (Time limit: M04)
03.01.2018Reply to a communication from the examining division
03.04.2018Despatch of a communication from the examining division (Time limit: M06)
15.10.2018Reply to a communication from the examining division
12.02.2019Despatch of a communication from the examining division (Time limit: M04)
21.06.2019Reply to a communication from the examining division
19.11.2019Communication of intention to grant the patent
11.03.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.03.2020Fee for grant paid
11.03.2020Fee for publishing/printing paid
20.04.2020Information about intention to grant a patent
20.04.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.01.2016
Opposition(s)02.03.2021No opposition filed within time limit [2021/18]
Fees paidRenewal fee
26.08.2014Renewal fee patent year 03
18.08.2015Renewal fee patent year 04
16.08.2016Renewal fee patent year 05
16.08.2017Renewal fee patent year 06
09.08.2018Renewal fee patent year 07
17.07.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.08.2012
AL27.05.2020
AT27.05.2020
CY27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MK27.05.2020
MT27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
TR27.05.2020
BG27.08.2020
GR28.08.2020
IE30.08.2020
LU30.08.2020
CH31.08.2020
FR31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
[2022/32]
Former [2022/27]HU30.08.2012
AL27.05.2020
AT27.05.2020
CY27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MT27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
TR27.05.2020
BG27.08.2020
GR28.08.2020
IE30.08.2020
LU30.08.2020
CH31.08.2020
FR31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2022/26]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
TR27.05.2020
BG27.08.2020
GR28.08.2020
IE30.08.2020
LU30.08.2020
CH31.08.2020
FR31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/37]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
IE30.08.2020
LU30.08.2020
CH31.08.2020
FR31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/35]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
LU30.08.2020
CH31.08.2020
FR31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/24]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SI27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
LU30.08.2020
CH31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/20]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
LU30.08.2020
CH31.08.2020
LI31.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/18]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/10]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
PL27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SK27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/09]AL27.05.2020
AT27.05.2020
CZ27.05.2020
DK27.05.2020
EE27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
IT27.05.2020
LT27.05.2020
LV27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/08]AL27.05.2020
DK27.05.2020
ES27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RO27.05.2020
RS27.05.2020
SE27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/04]AL27.05.2020
FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
SE27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2021/01]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
SE27.05.2020
BG27.08.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/51]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
SE27.05.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/50]FI27.05.2020
HR27.05.2020
LT27.05.2020
LV27.05.2020
SE27.05.2020
GR28.08.2020
IS27.09.2020
PT28.09.2020
Former [2020/48]FI27.05.2020
LT27.05.2020
SE27.05.2020
IS27.09.2020
PT28.09.2020
Former [2020/47]LT27.05.2020
IS27.09.2020
Former [2020/46]IS27.09.2020
Documents cited:Search[X]US6667392  (XIA JUSONG [US], et al) [X] 14 * examples 11-14, 23 *;
 [X]WO2004046167  (UNIV NORTHWESTERN [US], et al) [X] 14 * figure 5; compound 16 *;
 [X]US2005164235  (MANOHARAN MUTHIAH [US], et al) [X] 14 * compounds 14, 15, 17, 21,23, 32, 7, 33, 38, 39, 40, 43, 54 ** compound 61 *;
 [X]WO2010048582  (IRM LLC [US], et al) [X] 1-3,9 * examples 37-2 *;
 [E]WO2013072717  (CENTRE NAT RECH SCIENT [FR], et al) [E] 14 * example 1.2; compounds 13-17, 17-technecium complex * * claim 1 *;
 [X]  - MARION K. MÜLLER ET AL, "A Supramolecular Polymer as a Self-Assembling Polyvalent Scaffold", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, (20090406), vol. 48, no. 16, doi:10.1002/anie.200900143, ISSN 1433-7851, pages 2921 - 2924, XP055165306 [X] 1-3,9 * page 2922; compounds 2, 3 *

DOI:   http://dx.doi.org/10.1002/anie.200900143
 [X]  - Marion K. Müller ET AL, "Supporting Information for: A supamolecular polymer as self-assembling polyvalent scaffold", (20090101), pages S - 1, URL: http://onlinelibrary.wiley.com/store/10.1002/anie.200900143/asset/supinfo/anie_200900143_sm_miscellaneous_information.pdf?v=1&s=c3f23ef9b689897d0eb44eb652901e1a89b538d2, (20150127), XP055165327 [X] 1-3,9 * compounds 17, 18, 19, 21 *
 [X]  - ELODIE BOISSELIER ET AL, "Encapsulation and Stabilization of Gold Nanoparticles with "Click" Polyethyleneglycol Dendrimers", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20100303), vol. 132, no. 8, doi:10.1021/ja909133f, ISSN 0002-7863, pages 2729 - 2742, XP055165339 [X] 1-3 * page 2736; compound 3 * * page 2741, column left *

DOI:   http://dx.doi.org/10.1021/ja909133f
 [X]  - STEVE PO-YAM LI ET AL, "Modification of Luminescent Iridium(III) Polypyridine Complexes with Discrete Poly(ethylene glycol) (PEG) Pendants: Synthesis, Emissive Behavior, Intracellular Uptake, and PEGylation Properties", CHEMISTRY - A EUROPEAN JOURNAL, (20100702), vol. 16, no. 28, doi:10.1002/chem.201000474, ISSN 0947-6539, pages 8329 - 8339, XP055165385 [X] 1-4,9 * page 8330; compounds 1b, 2b *

DOI:   http://dx.doi.org/10.1002/chem.201000474
 [X]  - MARION K. MÜLLER ET AL, "Protein assembly along a supramolecular wire", CHEMICAL COMMUNICATIONS, (20110101), vol. 47, no. 1, doi:10.1039/c0cc02084b, ISSN 1359-7345, pages 310 - 312, XP055165369 [X] 1-3,9 * page 310; compounds 2, 3 *

DOI:   http://dx.doi.org/10.1039/C0CC02084B
 [XP]  - MATHIEU ARSENEAULT ET AL, "Efficient and Rapid Divergent Synthesis of Ethylene Oxide-Containing Dendrimers through Catalyst-Free Click Chemistry", MACROMOLECULES, (20120508), vol. 45, no. 9, doi:10.1021/ma300648r, ISSN 0024-9297, pages 3687 - 3694, XP055165515 [XP] 7,8 * scheme 2;; compounds EO2-EO4-G2-N3 and EO2EO4-G3-OTs *

DOI:   http://dx.doi.org/10.1021/ma300648r
 [X]  - GUTIERREZ-NAVA M ET AL, "Synthesis of copolymers alternating oligophenylenevinylene subunits and fullerene moieties", TETRAHEDRON LETTERS, PERGAMON, GB, (20030609), vol. 44, no. 24, doi:10.1016/S0040-4039(03)00991-2, ISSN 0040-4039, pages 4487 - 4490, XP004425247 [X] 14 * compound 5 *

DOI:   http://dx.doi.org/10.1016/S0040-4039(03)00991-2
 [X]  - JIAN-YONG LIU ET AL, "Highly photocytotoxic 1,4-dipegylated zinc(ii) phthalocyanines. Effects of the chain length on the in vitro photodynamic activities", ORGANIC & BIOMOLECULAR CHEMISTRY, (20080101), vol. 6, no. 24, doi:10.1039/b814627f, ISSN 1477-0520, page 4560, XP055165718 [X] 14 * compound 3d *

DOI:   http://dx.doi.org/10.1039/b814627f
 [X]  - TAKAHIRO MURAOKA ET AL, "Mimicking multipass transmembrane proteins: synthesis, assembly and folding of alternating amphiphilic multiblock molecules in liposomal membranes", CHEMICAL COMMUNICATIONS, (20110101), vol. 47, no. 1, doi:10.1039/c0cc02420a, ISSN 1359-7345, page 194, XP055165720 [X] 14,15 * compounds 2-4 *

DOI:   http://dx.doi.org/10.1039/C0CC02420A
 [X]  - HARRY W. GIBSON ET AL, "Difunctional derivatives of bis( m -phenylene)-32-crown-10", CANADIAN JOURNAL OF CHEMISTRY, (19971001), vol. 75, no. 10, doi:10.1139/v97-165, ISSN 0008-4042, pages 1375 - 1384, XP055165734 [X] 14 * compounds 7, 10-14 *

DOI:   http://dx.doi.org/10.1139/v97-165
 [XP]  - TOLLAS SZILVIA ET AL, "Nano-sized clusters of a teicoplanin [psi]-aglycon-fullerene conjugate. Synthesis, antibacterial activity and aggregation studies", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (20120704), vol. 54, doi:10.1016/J.EJMECH.2012.06.054, ISSN 0223-5234, pages 943 - 948, XP028932599 [XP] 14 * compounds 5-8, 10 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2012.06.054
International search[A]US5359030  (EKWURIBE NNOCHIRI N [US]);
 [A]US2006020134  (DAVIS PAUL D [US], et al);
 [X]US2007031371  (MCMANUS SAMUEL P [US], et al);
 [A]US2010210505  (BOSSARD MARY J [US], et al);
 [A]US2011124844  (DAVIS PAUL D [US], et al)
ExaminationWO2007080114
    - SHERLY QUILES ET AL, "Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, (20100128), vol. 53, no. 2, doi:10.1021/jm900899g, ISSN 0022-2623, pages 586 - 594, XP055127608

DOI:   http://dx.doi.org/10.1021/jm900899g
    - CHRISTINA C. CAPULE ET AL, "Oligovalent Amyloid-Binding Agents Reduce SEVI-Mediated Enhancement of HIV-1 Infection", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20120118), vol. 134, no. 2, doi:10.1021/ja210931b, ISSN 0002-7863, pages 905 - 908, XP055092256

DOI:   http://dx.doi.org/10.1021/ja210931b
by applicantUS4946778
 US6818749
 US7553816
 US2010164068
 US7888536
 US8119132
 US2012164068
    - H. MARK, "Purity and Identity of Polymers", Anal. Chem., (19480000), vol. 20, no. 2, pages 104 - 110
    - S. JEVS-EVARM. KUNSTELJV. GABERC POREKAR, "PEGylation of therapeutic proteins", Biotechnol. J., (20100000), vol. 5, pages 113 - 128
    - MOLINEUX, G., "The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)", Curr. Pharm. Des., (20040000), vol. 10, doi:doi:10.2174/1381612043452613, pages 1235 - 1244, XP009057064

DOI:   http://dx.doi.org/10.2174/1381612043452613
    - L. ZHU et al., "Real-Time Video Imaging of Protease Expression in Vivo", Theranostics, (20110000), vol. 1, pages 18 - 27
    - S. QUILES, "Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy", J. Med. Chem., (20100000), vol. 53, doi:doi:10.1021/jm900899g, pages 586 - 594, XP055127608

DOI:   http://dx.doi.org/10.1021/jm900899g
    - STEEVENS N. S. ALCONCELARNOLD S. BAASHEATHER D. MAYNARD, "FDA-approved poly(ethylene glycol)-protein conjugate drugs", Polym. Chem., (20110000), vol. 2, pages 1442 - 1448
    - E. M. SLETTENC. R. BERTOZZI, "Biorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality", Angew. Chem. Int. Ed., (20090000), vol. 48, doi:doi:10.1002/anie.200900942, pages 6974 - 6998, XP055056473

DOI:   http://dx.doi.org/10.1002/anie.200900942
    - "Releasable PEGylation of proteins with customized linkers,", DAVID FILPULAHONG ZHAO, Advances in Drug Delivery Reviews, Academic Press, (20080000), vol. 60, pages 29 - 49
    - M. FAMULOK et al., "Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy", Chem. Rev., (20070000), vol. 107, no. 9, doi:doi:10.1021/cr0306743, pages 3715 - 3743, XP002508782

DOI:   http://dx.doi.org/10.1021/cr0306743
    - ELLEN M. SLETTENCAROLYN R. BERTOZZI, "Biorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality", Angewandte Chemie Int. Ed., (20090000), vol. 48, doi:doi:10.1002/anie.200900942, pages 6974 - 6998, XP055056473

DOI:   http://dx.doi.org/10.1002/anie.200900942
    - CHANG C. LIUPETER G. SCHULTZ, "Adding New Chemistries to the Genetic Code", Annu. Rev. Biochem., (20100000), vol. 79, doi:doi:10.1146/annurev.biochem.052308.105824, pages 413 - 444, XP055026250

DOI:   http://dx.doi.org/10.1146/annurev.biochem.052308.105824
    - G.R. NEWKOMEC. SHREINER, "Dendrimers Derived from 1 .¿ 3 Branching Motifs", Chemical Reviews, (20100000), vol. 110, pages 6338 - 6442
    - HANS W. SCHEEREN et al., "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release", J. Org. Chem., (20010000), vol. 66, doi:doi:10.1021/jo0158884, pages 8815 - 8830, XP002212035

DOI:   http://dx.doi.org/10.1021/jo0158884
    - D. SCOTT WILBUR, "Chemical and Radiochemical Considerations in Radiolabeling with alpha-Emitting Radionuclides", Current Radiopharmaceuticals, (20110000), vol. 4, doi:doi:10.2174/1874471011104030214, pages 214 - 247, XP009501265

DOI:   http://dx.doi.org/10.2174/1874471011104030214
    - S. S. KELKART. M. REINEKE, "Theranostics: Combining Imaging and Therapy", Bioconjugate Chemistry, vol. 22, doi:doi:10.1021/bc200151q, pages 1879 - 1903, XP055013687

DOI:   http://dx.doi.org/10.1021/bc200151q
    - DAVID J. NEWMAN, "Impact of Natural Products on Developing New Anti-Cancer Agents", Chemical Reviews, (20090000), vol. 109, pages 3012 - 3043
    - M. FAMULOK, "Functional Aptamers and Atazymes in Biotechnology, Diagnostics, and Therapy", Chem. Rev., (20070000), vol. 107, no. 9, doi:doi:10.1021/cr0306743, page 3715, XP002508782

DOI:   http://dx.doi.org/10.1021/cr0306743
    - D. SCOTT WILBUR, "Chemical and Radiochemical Considerations in Radiolabeling with -Emitting Radionuclides", Current Radiopharmaceuticals, (20110000), vol. 4, doi:doi:10.2174/1874471011104030214, pages 214 - 247, XP009501265

DOI:   http://dx.doi.org/10.2174/1874471011104030214
    - D LIPOVSEK, "Adnectins: engineered target-binding protein therapeutics", Protein Engineering, Design & Selection, (20100000), pages 1 - 7
    - N. NEAMATI et al., "Integrin Targeted Therapeutics", Theranostics, (20110000), vol. 1, doi:doi:10.7150/thno/v01p0154, pages 154 - 188, XP002675313

DOI:   http://dx.doi.org/10.7150/thno/v01p0154
    - STEVEN H. L. VERHELST,MARKO FONOVIC'MATTHEW BOGYO, "A Mild Chemically Cleavable Linker System for Functional Proteomic Applications", Angew. Chem. Int. Ed., (20070000), vol. 46, pages 1 - 4
    - MARTIJN ROOSEBOOMJAN N. M. COMMANDEURNICO P. E. VERMEULEN, "nzyme-Catalyzed Activation of Anticancer Prodrugs,", Pharmacol Rev, (20040000), vol. 56, doi:doi:10.1124/pr.56.1.3, pages 53 - 102, XP002440401

DOI:   http://dx.doi.org/10.1124/pr.56.1.3
    - RICHARD B. GREENWALD et al., "Controlled Release of Proteins from Their Poly(Ethylene Glycol) Conjugates: Drug Delivery Systems Employing 1,6-Elimination", Bioconjugate Chem., (20030000), vol. 14, doi:doi:10.1021/bc025652m, pages 395 - 403, XP002318263

DOI:   http://dx.doi.org/10.1021/bc025652m
    - P.J. SINKO et al., "Recent Trends in Targeted Anticancer Prodrug and Conjugate Design", Curr. Med. Chem., (20080000), vol. 15, no. 18, doi:doi:10.2174/092986708785132997, pages 1802 - 1826, XP055269181

DOI:   http://dx.doi.org/10.2174/092986708785132997
    - J. RAUTIO et al., "Prodrugs: design and clinical applications", Nature Review, Drug Discovery, (20080000), vol. 7, doi:doi:10.1038/nrd2468, pages 255 - 270, XP055227338

DOI:   http://dx.doi.org/10.1038/nrd2468
    - JEONG et al., "Avimers hold their own", Nature Biotechnology, (20051200), vol. 23, no. 12
    - "Engineered protein scaffolds as next-generation antibody therapeutics", Michaela Gebauer and Arne Skerra, Current Opinion in Chemical Biology, (20090000), vol. 13, pages 245 - 255
    - XIAOYUAN CHEN et al., "Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis", Chemical Reviews, (20100000), vol. 110, doi:doi:10.1021/CR900361P, pages 3087 - 3111, XP002644588

DOI:   http://dx.doi.org/10.1021/CR900361P
    - YUNPENG YE et al., "Integrin Targeting for Tumor Optical Imaging", Theranostics, (20110000), vol. 1, pages 102 - 126
    - B. A. TEICHER, "Antibody-Drug Conjugate Targets", Current Cancer Drug Targets, (20090000), vol. 9, pages 982 - 1004
    - A. J. DE GRAAF, "Nonnatural Amino Acids for Site-Specific Protein Conjugation", Bioconjugate Chemistry, (20090000), vol. 20, no. 7, doi:doi:10.1021/bc800294a, pages 1281 - 1295, XP055025160

DOI:   http://dx.doi.org/10.1021/bc800294a
    - JUNG SEOK KANGPATRICK P DELUCAKANG CHOON LEE, "Emerging PEGylated drugs", Expert Opin. Emerging Drugs, (20090000), vol. 14, no. 2, doi:doi:10.1517/14728210902907847, pages 363 - 380, XP008164958

DOI:   http://dx.doi.org/10.1517/14728210902907847
    - DAVID FILPULAHONG ZHAO, "Releasable PEGylation of proteins with customized linkers", Advanced Drug Delivery Reviews, (20080000), vol. 60, doi:doi:10.1016/j.addr.2007.02.001, pages 29 - 49, XP022370570

DOI:   http://dx.doi.org/10.1016/j.addr.2007.02.001
    - FRANCESCO M. VERONESEGIANFRANCO PASUT, "PEGylation, successful approach to drug delivery", Drug Discovery Today, (20050000), vol. 10, no. 21, pages 1451 - 1458
    - YANLING, L. et al., "Effect of PEGylation on the Solution Conformation of Antibody Fragments", Journal of Pharmaceutical Sciences, (20080000), vol. 97, no. 6, pages 2062 - 2079
    - C. S. FISHBURN, "The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics", Journal of Pharmaceutical Sciences, (20080000), vol. 97, no. 10, doi:doi:10.1002/JPS.21278, pages 4167 - 4183, XP002725227

DOI:   http://dx.doi.org/10.1002/JPS.21278
    - D. S. WILBUR et al., "Streptavidin in Antibody Pretargeting. 3. Comparison of Biotin Binding and Tissue Localization of 1,2-Cyclohexanedione and Succinic Anhydride Modified Recombinant Streptavidin", Bioconjugate Chemistry, (20020000), vol. 13, doi:doi:10.1021/bc015574n, pages 611 - 620, XP001102386

DOI:   http://dx.doi.org/10.1021/bc015574n
    - MATEJA KUSTERLE et al., "Size of Pegylated Protein Conjugates Studied by Various Methods", Acta Chimica Slovenia, (20080000), vol. 55, pages 594 - 601, XP055139109
    - R. D. TILTON et al., "The Conformation of the Poly(ethylene glycol) Chain in Mono-PEGylated Lysozyme and Mono-PEGylated Human Growth Hormone", Bioconjugate Chemistry, (20110000), vol. 22, no. 11, doi:doi:10.1021/bc2003583, pages 2317 - 2323, XP055430593

DOI:   http://dx.doi.org/10.1021/bc2003583
    - DAVID FILPULA et al., "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A comparison of Conjugation Chemistries and Componds", Bioconjuate Chemistry, (19990000), vol. 10, doi:doi:10.1021/BC990076O, pages 973 - 981, XP002640452

DOI:   http://dx.doi.org/10.1021/BC990076O
    - CONAN J. FEE, "Size Comparison Between Proteins PEGylated with Branched and Linear Poly(Ethylene Glycol) Molecules", Biotechnology and Bioengineering, (20070000), vol. 98, no. 4, pages 725 - 731
    - CONAN J. FEEJAMES M. VAN ALSTINE, "Prediction of the Viscosity Radius and the size Exclusion Chromatography Behavior of PEGylated Proteins", Bioconjugate Chemistry, (20040000), vol. 15, pages 1304 - 1313
    - MATEJA KUSTERLE et al., "Correlations between in vitro potency of poly(ethylene glycol-protein conjugates and their chromatographic behavior", Analytical Biochemistry, (20090000), vol. 389, pages 27 - 31
    - MATEJA KUSTERLE et al., "The Characterization and Potential Use of G-CSF Dimers and their Pegylated Conjugates", Acta Chimica Slovenia, (20110000), vol. 58, pages 1 - 8, XP055166499
    - PASCAL BAILON et al., "Rational Design of a Potent, Long-Lasting Form of interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon alpha-2a for the Treatment of Hepatitis C", Bioconjugate Chemistry, (20010000), vol. 12, doi:doi:10.1021/bc000082g, pages 195 - 202, XP002264676

DOI:   http://dx.doi.org/10.1021/bc000082g
    - MARY S. ROSENDAHL, "A Long-Acting, Highly Potent Interferon alpha-2 Conjugate Created Using Site-Specific PEGylation", Bioconjugate Chemistry, (20050000), vol. 16, pages 200 - 207
    - HANS SENN, et al., "Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha-2a and Its Individual Positional Isomers", Bioconjugate Chemistry, (20050000), vol. 16, doi:doi:10.1021/bc049781+, page 504, XP055258109

DOI:   http://dx.doi.org/10.1021/bc049781+
    - HANS SENN et al., "Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG-Interferon-alpha-2a and Its Individual Positional isomers to the Extracellular Domain of the Receptor IFNAR2", Bioconjugate Chemistry, (20050000), vol. 16, pages 518 - 527
    - DELGADO et al., British J. Cancer, (19960000), vol. 73, pages 175 - 182
    - LIN LI et al., "Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA Diabody", Bioconjugate Chemistry, (20060000), vol. 17, doi:doi:10.1021/bc0502614, pages 68 - 76, XP055072586

DOI:   http://dx.doi.org/10.1021/bc0502614
    - L. LI, "Site-Specific Conjugation of Monodispersed DOTA-PEGn to a Thiolated Diabody Reveals the Effect of Increasing PEG Size on Kidney Clearance and Tumor Uptake with Improved 64-Copper PET Imaging", Bioconjugate Chemistry, (20110000), vol. 22, no. 4, pages 709 - 716
    - Y. LI et al., "MALDI-TOF Mas Spectral Characterization of Polymers Containing an Azide Group: Evidence of Metastable Ions", Macromolecules, (20100000), vol. 43, no. 14, pages 6225 - 6228
    - ANNA MEROBARBARA SPOLAOREFRANCESCO M. VERONESEANGELO FONTANA, "Transglutaminase-Mediated PEGylation of Proteins: Direct Identification of the Sites of Protein Modification by Mass Spectrometry using a Novel Monodisperse PEG", Bioconjugate Chem., (20090000), vol. 20, no. 2, doi:doi:10.1021/bc800427n, pages 384 - 389, XP055418460

DOI:   http://dx.doi.org/10.1021/bc800427n
    - GEORGE R. NEWKOMEKISHORE K. KOTTACHARLES N. MOOREFIELD, "Convenient Synthesis of 1 .¿3 C-Branched Dendrons", J. Org. Chem., (20050000), vol. 70, pages 4893 - 4896
    - GEORGE R. NEWKOMECAROL SHREINER, "Dendrimers Derived from 1 3 Branching Motifs", Chem. Rev., (20100000), vol. 110, pages 6338 - 6442
    - K. C. KUMARA SWAMY, "Mitsunobu and Related Reactions: Advances and Applications", Chem. Rev., (20090000), vol. 109, doi:doi:10.1021/cr800278z, pages 2551 - 2651, XP055023394

DOI:   http://dx.doi.org/10.1021/cr800278z
    - A. J. DEGRAAF et al., "Non-natural Amino Acids for Site-Specific Protein Conjugation", Bioconjugate Chemistry, vol. 20, no. 7, pages 1281 - 1295
    - PETER G. SCHULTZLEI WANG, "Expanding the Genetic Code,", Angew. Chem. Int. Ed., (20050000), vol. 44, pages 34 - 66
    - M. MAMMEN, "Polyvalent Interactions in Biological sSystems: Implications for Design and Use of Multivalent Ligands and Inhibitors", Angew. Chem. Int. Ed., (19980000), vol. 37, doi:doi:10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3, pages 2754 - 2794, XP002960955

DOI:   http://dx.doi.org/10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
    - D. ANDREU, "Strategies and Limitations in Dendrimeric Immunogen Synthesis: The Influenza Virus M2e Epitope as a Case Study", Bioconjugate Chemistry, (20100000), vol. 21, pages 102 - 110
    - P.M.H. HEEGAARD et al., "Dendrimers for Vaccine and Immunostimulatory Uses. A Review", Bioconjugate Chemistry, (20100000), vol. 21, doi:doi:10.1021/bc900290d, pages 405 - 418, XP055055308

DOI:   http://dx.doi.org/10.1021/bc900290d
    - M. GEBAUERA. SKERRA, "Engineered protein scaffolds as next-generation antibody therapeutics", Curr. Opin. Chem. Biol., (20090000), vol. 13, pages 245 - 255
    - A. B. VAN SPRIEL et al., "immunotherapeutic perspective for bispecfic antibodies", Immunology Today, (20000000), vol. 21, no. 8, pages 391 - 397
    - P. CHAMESD. BATY, "Bispecific antibodies for cancer therapy: The light at the end of the tunnel?", Landes Bioscience, (20090000), vol. 1, no. 6, doi:doi:10.4161/mabs.1.6.10015, pages 539 - 546, XP002688758

DOI:   http://dx.doi.org/10.4161/mabs.1.6.10015
    - D. J. CAPON, "Flexible antibodies with non-protein hinges", Proc. Jpn. Acad., Ser. B, (20110000), vol. 87, pages 603 - 616
    - T. H. KIM, "Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics", Bioconjugate Chemistry, (20110000), vol. 22, doi:doi:10.1021/bc100404x, pages 625 - 632, XP055138198

DOI:   http://dx.doi.org/10.1021/bc100404x
    - T. H. KIM, "Low Molecular Weight (1 kDa) Polyethylene Glycol Conjugation Markedly Enhances the Hypoglycemic Effects of Intranasally Administered Exendin-4 in Type 2 Diabetic db/db Mice", Biol. Pharm. Bull, (20120000), vol. 35, no. 7, doi:doi:10.1248/bpb.b12-00029, pages 1076 - 1083, XP055170987

DOI:   http://dx.doi.org/10.1248/bpb.b12-00029
    - M. GEBAUERA. SKERRA, "Engineered protein scaffolds as next-generation antibody therapeutics", Current Opinion in Chemical Biology, (20090000), vol. 13, pages 245 - 255
    - CHRISTOPHER J. MURRAY et al., "Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production-A New Approach for Shortening Protein Production Development Timelines", Biotechnology and Bioengineering, (20110000), vol. 108, no. 7, doi:doi:10.1002/bit.23103, pages 1570 - 1578, XP055543387

DOI:   http://dx.doi.org/10.1002/bit.23103
    - L. LI,, J. Nucl. Med., (20100000), vol. 51, pages 1139 - 1146
    - JAMES R. WILD et al., "Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol", Journal of Controlled Release, (20100000), vol. 146, pages 318 - 325, XP027260362
    - M.R. SHERMAN et al., "Role of the Methoxy Group in Immune Responses to m-PEG-Protein Conjugates", Bioconjugate Chemistry, (20120000), vol. 23, pages 485 - 499
    - NAOKI SHOZENISSEI LIJIMATAKAHIRO HOHSAKA, "Site-specific incorporation of PEGylated amino acids into proteins using non-natural amino acid mutagenesis", Bioorganic & Medicinal Chemistry Letters, (20090000), vol. 19, pages 4909 - 4911
    - D. SCOTT WILBUR et al., "Monoclonal Antibody Fab' Fragment Cross-Linking Using Equilibrium Transfer Alkylation Reagents. A Strategy for Site-Specific Conjugation of Diagnostic and Therapeutic Agents with F(ab')2 Fragments", Bioconjugate Chemistry, (19940000), vol. 5, doi:doi:10.1021/bc00027a007, pages 220 - 235, XP002313937

DOI:   http://dx.doi.org/10.1021/bc00027a007
    - JENNIFER A PRESCHERCAROLYN R BERTOZZI, "Chemistry in living systems", Nature Chemical Biology, (20050000), vol. 1, doi:doi:10.1038/nchembio0605-13, pages 13 - 21, XP002410570

DOI:   http://dx.doi.org/10.1038/nchembio0605-13
    - NAOKI SHOZENISSEI LIJIMATAKAHIRO HOHSAKA, "Site-specific incorporation of PEGylated amino acids into proteins using endron ralral amino acid mutagenesis", Bioorganic & Medicinal Chemistry Letters, (20090000), vol. 19, pages 4909 - 4911
    - DAVID ZOPF et al., "GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli", Glycobiology, (20060000), vol. 16, doi:doi:10.1093/glycob/cwl004, pages 833 - 843, XP002403450

DOI:   http://dx.doi.org/10.1093/glycob/cwl004
    - CAROLYN R BERTOZZI et al., "Introducing genetically encoded aldehydes into proteins", Nature Chemical Biology, (20070000), vol. 3, no. 3-1, page 322
    - CAROLYN R. BERTOZZI et al., "Function and Structure of a Prokaryotic Formylglycine-generating Enzyme", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20080718), vol. 283, no. 29, doi:doi:10.1074/jbc.M800217200, pages 20117 - 20125, XP002712380

DOI:   http://dx.doi.org/10.1074/jbc.M800217200
    - JASON S. RUSHCAROLYN R. BERTOZZI, "New Aldehyde Tag Sequences Identified by Screening Formylglycine Generating Enzymes in Vitro and in Vivo", J. Am. Chem. Soc., (20080000), vol. 130, no. 37, doi:doi:10.1021/ja804530w, pages 12240 - 12241, XP002712387

DOI:   http://dx.doi.org/10.1021/ja804530w
    - CAROLYN R. BERTOZZI et al., "Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag", PNAS, (20090000), vol. 106, no. 9, doi:doi:10.1073/pnas.0807820106, pages 3000 - 3005, XP055050093

DOI:   http://dx.doi.org/10.1073/pnas.0807820106
    - PETER SCHULTZLEI WANG, "Expanding the Genetic Code", Angew. Chem. Int. Ed., (20050000), vol. 44, pages 34 - 66
    - CHANG C. LIUPETER G. SCHULTZADDING TO THE GENETIC CODE, Annu. Rev. Biochem., (20100000), vol. 79, pages 413 - 444
    - "Unnaturally Productive", c&ENews, (20110822), page 40
    - EUNKEU OH et al., "Cellular Uptake and the Fate of PEGylated Gold Nanoparticles Is Dependent on Both Cell-Penetration Peptide and Particle Size", ACSNano, (20110000), vol. 5, no. 8, pages 6434 - 6448
    - DANIELA AROSIO et al., "Cyclic RGD Functionalized Gold Nanoparticles for Tumor Targeting", Bioconjugate Chemistry, (20110000), vol. 22, doi:doi:10.1021/bc100448r, pages 664 - 672, XP055446614

DOI:   http://dx.doi.org/10.1021/bc100448r
    - DAVID CLIFFEL et al., "Short Chain PEG Mixed Monolayer Protected God Clusters Increase Clearance and Red Blook Cell Counts", ACSNano, (20110000), vol. 5, pages 3577 - 3584
    - "Conjugation of Peptides to the Passivation Shell of Gold Nanoparticles for Targeting of Cell-Surface Receptors", ACSNano, (20100000), vol. 4, pages 6617 - 6628
    - STEVEN M. LARSEN, "Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma", J Clin Invest
    - SUNG MIN DANG et al., "Biomimetic approach to the formatin of gold nanoparticle/silic core/shell structures and subsequent bioconjugation", Nanotechnology, (20060000), vol. 17, pages 4719 - 4725
    - TAKESHI SERIZAWA et al., "Novel Synthetic Route to Peptide-Capped Gold Nanoparticles", Langmuir, (20090000), vol. 25, no. 20, doi:doi:10.1021/la9021799, pages 12229 - 12234, XP055385054

DOI:   http://dx.doi.org/10.1021/la9021799
    - ROBERTO FIAMMENGO et al., "Conjugation of Peptides to the Passivation Shell of god Nanoparticles for Targeting of Cell-Surface Receptors", ACSNano, (20100000), vol. 4, no. 11, doi:doi:10.1021/nn101867w, pages 6617 - 6628, XP002714555

DOI:   http://dx.doi.org/10.1021/nn101867w
    - LISA BRANNON-PEPPAS et al., "PEGylation strategies for active targeting of PLA/PLGA nanoparticles", Journal of Biomedical Materials Research Part A., (20080000), pages 263 - 276
    - VINESS PILLAY et al., "A Review on Composite Liposomal Technologies for Specialized Drug Delivery", Journal of Drug Delivery, (20110000), pages 1 - 19
    - IGOR L. MEDINTZ et al., "The Controlled Display of Biomolecules on Nanoparticles: A Challenge Suited to Bioorthogonal Chemistry", Bioconjugate Chemistry, (20110000), vol. 22, doi:doi:10.1021/bc200065z, pages 825 - 858, XP055065266

DOI:   http://dx.doi.org/10.1021/bc200065z
    - RUMIANA BAKALOVA et al., "Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics", International Journal of Nanomedicine,, (20110000), vol. 6, pages 1719 - 1732
    - JASON MICKLEFIELD et al., "Selective Covalent Protein Immobilization: Strategies and Applications", Chemical Reviews, (20090000), vol. 109, doi:doi:10.1021/cr8004668, pages 4025 - 4053, XP055100447

DOI:   http://dx.doi.org/10.1021/cr8004668
    - TAICHI ISHITSUKA et al., "Functional Improvement of an IRQ-PEG-MEND for delivering genes to the lung", Journal of Controlled Release, (20110000), vol. 154, no. 1, pages 77 - 83
    - "Antistaphylococcal Nanocomposite Films Based on Enzyme Nanotube Conjugates", ACS Nano, (20100000), vol. 4, no. 7, pages 3993 - 4000
    - KIYOSHI MATSUMOTO et al., "Development of a sensitive surface plasmon resonance immunosensor for detection of 2,4-dinitrotoluene with a novel oligo (ethylene glycol)-based sensor surface", Talanta, (20090000), vol. 79, doi:doi:10.1016/j.talanta.2009.02.018, pages 1142 - 1148, XP026319348

DOI:   http://dx.doi.org/10.1016/j.talanta.2009.02.018
    - GAZDAR AFCHICK WLOIE HKSIMS HLKING DLWEIR GCLAURIS V, "Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor", Proc Natl Acad Sci U S A, (19800000), vol. 77, doi:doi:10.1073/pnas.77.6.3519, pages 3519 - 3523, XP009006582

DOI:   http://dx.doi.org/10.1073/pnas.77.6.3519
    - GOKE RFEHMANN HLINN TSCHMIDT HKRAUSE MENG JGOKE B, "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells", The Journal of Biological Chemistry, (19930000), vol. 268, pages 19650 - 19655, XP002966930
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.